HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

epoetin beta

A recombinant form of erthropoietin that contains the 165 amino acid erythropoietin sequence. It differs from other epoetins by its distinct glycosylation pattern.
Also Known As:
NeoRecormon; Recormon; recombinant 1-165-erythropoietin glycoform beta; 1-165-erythropoietin (human clone lamdaHEPOFL13 protein moiety), glycoform beta
Networked: 198 relevant articles (30 outcomes, 79 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Locatelli, Francesco: 8 articles (01/2011 - 07/2002)
2. Scherhag, Armin: 7 articles (11/2010 - 01/2005)
3. Ohashi, Yasuo: 5 articles (12/2016 - 10/2006)
4. Saijo, Nagahiro: 5 articles (04/2013 - 08/2006)
5. Macdougall, Iain C: 5 articles (03/2012 - 06/2003)
6. Aapro, Matti: 5 articles (11/2009 - 01/2004)
7. Osterborg, Anders: 4 articles (11/2012 - 05/2002)
8. Burger, Hans-Ulrich: 4 articles (11/2010 - 10/2006)
9. Scherhag, A: 4 articles (12/2009 - 01/2006)
10. Coiffier, Bertrand: 3 articles (11/2012 - 08/2003)

Related Diseases

1. Anemia
2. Neoplasms (Cancer)
3. Renal Insufficiency (Renal Failure)
4. Lymphoma (Lymphomas)
5. Chronic Renal Insufficiency
10/01/2008 - "Anaemia in patients with chronic kidney disease: management with epoetin beta in primary care setting in New Zealand."
01/01/2013 - "We performed a meta-analysis of randomized trials evaluating ESA in adult patients with chronic kidney disease on dialysis (target Hb 9-13.5 g dl(-1)), and compared mean Hb and its standard deviation (SD), and ESA dose and its coefficient of variation (CV) between the different agents [rHuEPO alfa or beta, darbepoetin alfa, pegylated-epoetin beta (PEG-EPO) or other epoetins]. "
01/01/2005 - "Interestingly, >90% of the patients had concomitant mild-to-moderate chronic kidney disease at baseline and study end (CKD), as defined by the accepted diagnostic criterion of a CCr <60 ml/min. The correction of the anaemia with epoetin beta together with initial intravenous iron supplementation, resulted in significant improvements in NYHA class and cardiac function, and a reduction in hospitalization rate. "
01/01/2005 - "This observation was made primarily in cases where one brand of epoetin, Eprex, was administered subcutaneously to patients with chronic kidney disease treated outside the United States, although a small number of cases among chronic kidney disease patients treated solely with epoetin beta were also identified. "
06/01/2003 - "The ongoing Cardiovascular risk Reduction by Early Anaemia Treatment with Epoetin beta (CREATE) trial is investigating the effect of early anaemia correction in around 600 patients with moderate anaemia [haemoglobin (Hb) 11.0-12.5 g/dl] and chronic kidney disease (CKD) not yet requiring renal replacement therapy (creatinine clearance 15-35 ml/min). "

Related Drugs and Biologics

1. Erythropoietin
2. Hemoglobins (Hemoglobin)
3. Hormones (Hormone)
4. Darbepoetin alfa (Aranesp)
5. Epoetin Alfa (Epogen)
6. Iron
7. Granulocyte Colony-Stimulating Factor (G-CSF)
8. Platinum
9. epoetin omega
10. epoetin beta

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Renal Dialysis (Hemodialysis)
3. Therapeutics
4. Intravenous Administration
5. Chemoradiotherapy